Skip to main content
. 2024 Jul 2;25(13):7277. doi: 10.3390/ijms25137277

Figure 5.

Figure 5

Cancer drugs targeting Src, PI3K, or Akt reduce lipid droplet accumulation in PNPLA3∆1/∆2 iPSC-derived hepatocytes. (A) Graphs displaying the results of the dose–response assays assessing lipid droplet accumulation in PNPLA3∆1/∆2 with increasing concentrations of cancer drugs targeting Src, PI3K, or Akt (n ≥ 3, mean ± SEM, ANOVA compared to DMSO, * p ≤ 0.05, *** p ≤ 0.001, and **** p ≤ 0.0001). (B) Graphs showing cell viability of PNPLA3∆1/∆2 cells treated with different concentrations of cancer drugs in clinical trials (n ≥ 3, mean ± SEM, ANOVA compared to DMSO, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001).